Trenonacog Alfa

Summary

Trenonacog Alfa (CHEMBL3039538) is a phase-3 clinical-stage unknown; indicated across 6 conditions including hemophilia b and ataxia telangiectasia.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 6 conditions
• Clinical trials: 6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3039538
Name	Trenonacog Alfa
Type	Unknown
Max phase	3

Also known as: IB-1001, IB1001, Ixinity[tm], Trenonacog alfa, TRENONACOG ALFA

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

6 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
hemophilia B	3	MONDO:0010604	MONDO:0010604
ataxia telangiectasia	2	MONDO:0008840	MONDO:0008840
Sandhoff disease	2	MONDO:0010006	MONDO:0010006
Tay-Sachs disease	2	MONDO:0010100	MONDO:0010100
Niemann-Pick disease type C	2	MONDO:0018982	MONDO:0018982
GM2 gangliosidosis	2	MONDO:0017720	MONDO:0017720

Clinical trials

Total trials: 6.

Phase distribution

Phase	Trials
PHASE2	3
PHASE3	2
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00768287	PHASE2/PHASE3	COMPLETED	Study of Recombinant Factor IX Product, IB1001, in Subjects With Hemophilia B
NCT01271868	PHASE3	TERMINATED	Study of Recombinant Factor IX Product, IB1001, in Previously Treated Pediatric Subjects With Hemophilia B
NCT02048111	PHASE3	WITHDRAWN	Study of Recombinant Factor IX Product, IB1001, in Previously Treated Subjects With Hemophilia B
NCT03759639	PHASE2	COMPLETED	N-Acetyl-L-Leucine for Niemann-Pick Disease, Type C (NPC)
NCT03759665	PHASE2	COMPLETED	N-Acetyl-L-Leucine for GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease)
NCT03759678	PHASE2	TERMINATED	N-Acetyl-L-Leucine for Ataxia-Telangiectasia (A-T)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).